Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304). The company said it will continue to explore licensing opportunities for its preclinical anti-complement programs, including CB 2782, a protease derived from human membrane type serine protease 1 (MTSP-1) that cleaves complement factor 3 (C3) to treat delayed graft function, and an anti-C3 protease to treat dry age-related macular degeneration (AMD). Catalyst expects to complete the reduction by 4Q16. ...